Drug & intervention
amivantamab
RxCUI 2549199
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Clinical trials
20 shownA Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLCNCT07586202 · 2026-07-28
RECRUITINGA Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung CancerNCT07227025 · 2026-03-03
RECRUITINGPhase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations.NCT07392658 · 2025-12-02
RECRUITINGA Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT06667076 · 2024-12-16
RECRUITINGA Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerNCT05498428 · 2022-11-11
RECRUITINGA Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung CancerNCT06532032 · 2024-07-23
COMPLETEDPhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung CancerNCT06083857 · 2024-06-18
ACTIVE_NOT_RECRUITINGA Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor MutationsNCT05801029 · 2023-07-18
ACTIVE_NOT_RECRUITINGAmivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor MutationsNCT05299125 · 2023-05-24
COMPLETEDA Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung CancerNCT05908734 · 2023-05-18
ACTIVE_NOT_RECRUITINGPremedication to Reduce Amivantamab Associated Infusion Related ReactionsNCT05663866 · 2023-05-18
ACTIVE_NOT_RECRUITINGAmivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKINCT05601973 · 2023-03-27
ACTIVE_NOT_RECRUITINGA Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung CancerNCT05488314 · 2022-12-13
ACTIVE_NOT_RECRUITINGA Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib FailureNCT04988295 · 2021-11-17
ACTIVE_NOT_RECRUITINGA Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)NCT04965090 · 2021-09-30
COMPLETEDA Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 InsertionsNCT04538664 · 2020-10-13
ACTIVE_NOT_RECRUITINGA Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT04487080 · 2020-09-30
ACTIVE_NOT_RECRUITINGA Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung CancerNCT04077463 · 2019-09-04
ACTIVE_NOT_RECRUITINGStudy of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung CancerNCT02609776 · 2016-05-24
ACTIVE_NOT_RECRUITINGPre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung CancerNCT04599712
APPROVED_FOR_MARKETINGConditions being studied
Carcinoma, Non-Small-Cell Lung12Metastatic Non Small Cell Lung Cancer1Metastatic Non-Small Cell Lung Cancer1Metastatic Non-small Cell Lung Cancers1Metastatic NSCLC - Non-Small Cell Lung Cancer1Non Small Cell Lung Cancer1Non-small Cell Lung Cancer1Non-Small Cell Lung Cancer (NSCLC)1Non-Small-Cell Lung Cancer1Recurrent Non Small Cell Lung Cancer1
Research locations
Leading sponsors
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.